files/journal/2022-09-02_12-25-11-000000_331.png

International Journal of Tropical Medicine

ISSN: Online 1818-779X
ISSN: Print 1816-3319
About US
Editors
Issues
Pages
Indexed in

International Journal of Tropical Medicine, Volume 18, Issue 1 (2023)

References

  1. WHO., 2022. The global health observatory. Blood pressure/hypertension, https://www.who.int/data/gho/indicator-metadata-registry/imr-details/3155.
  2. WHO., 2022. Hypertension., https://www.who.int/health-topics/hypertension#tab=tab_1.
  3. WHO., 2010. Global status report on noncommunicable diseases. World Health Organization, Geneva., https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)62383-1/fulltext?_eventId%3Dlogin#back-bib21.
  4. Gupta, R. and D. Xavier, 2018. Hypertension: The most important non communicable disease risk factor in India. Indian Heart J., 70: 565-572.
  5. National Family Health Survey (NFHS-5), 2019. Key indicators. International Institute for Population Sciences, http://rchiips.org/NFHS/NFHS-5_FCTS/NFHS-5%20State%20Factsheet%20Compendium_Phase-I.pdf.
  6. Eckel, R.H., S.M. Grundy and P.Z. Zimmet, 2005. The metabolic syndrome. Lancet, 365: 1415-1428.
  7. Kalra, S. and A.G. Unnikrishnan, 2012. Obesity in India: The weight of the nation. J. Med. Nutr. Nutraceut., 1: 37-41.
  8. Ng, M., T. Fleming, M. Robinson, B. Thomson and N. Graetz et al., 2014. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: A systematic analysis for the global burden of disease study 2013. The Lancet, 384: 766-781.
  9. Obesity, V.S.S., 2012. Metabolic syndrome and Non communicable diseases. J. Res. Ext. Dev., 1: 7-13.
  10. Zimmet, P., 2000. Globalization, coca-colonization and the chronic disease epidemic: Can the doomsday scenario be averted? J. Int. Med., 247: 301-310.
  11. Wang, Y., 2004. Epidemiology of childhood obesity-methodological aspects and guidelines: What is new? Int. J. Obesity, 28:.
  12. WHO., 2000. Obesity: Preventing and Managing the Global Epidemic. World Health Organization, Geneva, ISBN-10: 9241208945, Pages: 268.
  13. WHO., 1995. Physical status: The use of and interpretation of anthropometry, report of a WHO expert committee., https://apps.who.int/iris/handle/10665/37003.
  14. Schulman, I.H. and M.S. Zhou, 2009. Vascular insulin resistance: A potential link between cardiovascular and metabolic diseases. Curr. Hypertens. Rep., 11: 48-55.
  15. Khoshdel, A.R., S.L. Carney and A. Gillies, 2012. Circulatory syndrome: An evolution of the metabolic syndrome concept!. Curr. Cardiol. Rev., 8: 68-76.
  16. Sowers, J.R., 2004. Insulin resistance and hypertension. Am. J. Physiol. Heart Circulatory Physiol., 286:.
  17. Pinhas-Hamiel, O., L.M. Dolan, S.R. Daniels, D. Standiford, P.R. Khoury and P. Zeitler, 1996. Increased incidence of non-insulin-dependent diabetes mellitus among adolescents. Elsevier BV, J. Pediatr., 128: 608-615.
  18. Fagot-Campagna, A., D.J. Pettitt, M.M. Engelgau, N.R. Burrows and L.S. Geiss et al., 2000. Type 2 diabetes among north adolescents: An epidemiologic health perspective. The J. Pediatr., 136: 664-672.
  19. Lucas, C.P., J.A. Estigarribia, L.L. Darga and G.M. Reaven, 1985. Insulin and blood pressure in obesity.. Hypertension, 7: 702-706.
  20. Modan, M., H. Halkin, S. Almog, A. Lusky and A. Eshkol et al., 1985. Hyperinsulinemia: A link between hypertension obesity and glucose intolerance.. J. Clin. Invest., 75: 809-817.
  21. Shen, D.C., S.M. Shieh, M.M.T. Fuh, D.A. Wu, Y.D.I. Chen and G.M. Reaven 1988. Resistance to insulin-stimulated-glucose uptake in patients with hypertension. J. Clin. Endocrinol. Metab., 66: 580-583.
  22. Landsberg, L. and D.R. Krieger, 1989. Obesity, metabolism, and the sympathetic nervous system. Am. J. Hypertens., 2: 125-132.
  23. Swislocki, A.L.M., B.B. Hoffman and G.M. Reaven, 1989. Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am. J. Hypertens., 2: 419-423.
  24. Pollare, T., H. Lithell and C. Berne, 1990. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism, 39: 167-174.
  25. Reaven, G.M., 1991. Relationship between insulin resistance and hypertension. Diabetes Care, 14: 33-38.
  26. Collins, V.R., G.K. Dowse, C.F. Finch and P.Z. Zimmet, 1990. An inconsistent relationship between insulin and blood pressure in three Pacific Island populations. J. Clin. Epidemiol., 43: 1369-1378.
  27. Mbanya, J.C., R. Wilkinson, T. Thomas, K. Alberti and R. Taylor, 1988. Hypertension and hyperinsulinemia: A relation in diabetes but not essential hypertension. Lancet, 331: 711-734.
  28. Leitner, D.R., G. Frühbeck, V. Yumuk, K. Schindler, D. Micic, E. Woodward and H. Toplak, 2017. Obesity and type 2 diabetes: Two diseases with a need for combined treatment strategies-EASO can lead the way. Obesity Facts, 10: 483-492.
  29. Hossain, P., B. Kawar and M.E. Nahas, 2007. Obesity and diabetes in the developing world: A growing challenge. New Engl. J. Med., 356: 213-215.
  30. Vasanthakumar, J. and S. Kambar, 2020. Prevalence of obesity among type 2 diabetes mellitus patients in urban areas of Belagavi. Indian J. Health Sci. Biomed. Res. (KLEU), 13: 21-27.
  31. Akholkar, P. and A. Gandhi, 2015. Prevalence of obesity in diabetic and non-diabetic population. Int. J. Res. Med. Sci., 3: 2114-2117.
  32. Babu, G.R., G. Murthy, Y. Ana, P. Patel and D. R et al., 2018. Association of obesity with hypertension and type 2 diabetes mellitus in India: A meta-analysis of observational studies. World J. Diabetes, 9: 40-52.
  33. Kumar, C., K. Kiran, V. Sagar and M. Kumar, 2016. Association of hypertension with obesity among adults in a rural population of Jharkhand. Int. J. Med. Sci. Public Health, 5: 2545-2549.
  34. Mitra, C., M. Lal, A. Mitra, A. Kaur and R. Gupta, 2021. A study to determine the role of modifiable and non-modifiable risk factors for hypertension among rural population of district Amritsar. Nat. J. Physiol., Pharm. Pharmacol., 11: 1257-1260.
  35. Ross, R., I.J. Neeland, S. Yamashita, I. Shai and J. Seidell et al., 2020. Waist circumference as a vital sign in clinical practice: A consensus statement from the IAS and ICCR working group on visceral obesity. Nat. Rev. Endocrinol., 16: 177-189.
  36. Parente, E.B., 2016. Is body mass index still a good tool for obesity evaluation? Arch. Endocrinol. Metab., 60: 507-509.
  37. Després, J.P., 2012. Body fat distribution and risk of cardiovascular disease. Circulation, 126: 1301-1313.
  38. Browning, L.M., S.D. Hsieh and M. Ashwell, 2010. A systematic review of waist-to-height ratio as a screening tool for the prediction of cardiovascular disease and diabetes: 0·5 could be a suitable global boundary value. Nutr. Res. Rev., 23: 247-269.
  39. Ashwell, M., P. Gunn and S. Gibson, 2011. Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: Systematic review and meta-analysis. Obesity Rev., 13: 275-286.
  40. Raji, A., E.W. Seely, R.A. Arky and D.C. Simonson, 2001. Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians. J. Clin. Endocrinol. Metab., 86: 5366-5371.
  41. Snehalatha, C. and A. Ramachandran, 1999. Insulin resistance in Asian Indians. PracT. Diabetes Int., 16: 19-22.
  42. Reaven, G.M., 2003. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J. Clin. Endocrinol. Metab., 88: 2399-2403.
  43. Saad, M.F., M. Rewers, J. Selby, G. Howard and S. Jinagouda et al., 2004. Insulin resistance and hypertension: The insulin resistance atherosclerosis study. Hypertension, 43: 1324-1331.
  44. Baioumi, A.Y.A.A., 2019. Comparing Measures of Obesity: Waist Circumference, Waist-Hip, and Waist-Height Ratios. In: Nutrition in the Prevention and Treatment of Abdominal Obesity, Watson, R.R., (Ed.)., Elsevier, ISBN-17: 978-0-12-816093-0, pp: 29-40.
  45. Mohanan, S., G. Nair, J. Maliekkal and S. Salim, 2022. A case-control study to assess the association of obesity and insulin resistance in hypertension at a tertiary care hospital in North Kerala. Nat. J. Physiol., Pharm. Pharmacol., 12: 1182-1186.